Personalis (NASDAQ:PSNL) (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.
In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development. These include targeted oncology panels, whole exome sequencing (WES) and RNA sequencing (RNA‐Seq) services, as well as specialty assays for infectious disease research. Personalis combines its laboratory operations—based in Menlo Park, California—with cloud‐based analytics to deliver scalable, quality‐controlled data across research and clinical workflows.
Founded in 2011 and headquartered in Menlo Park, California, Personalis completed its initial public offering in July 2014. Since then, the Company has expanded its geographic reach, serving customers across North America, Europe and Asia. Its laboratories maintain CLIA certification and CAP accreditation, enabling support for both research‐use and regulated clinical applications. Personalis also collaborates with pharmaceutical and biotechnology partners on co‐development programs to accelerate the translation of genomic data into novel therapies.
Personalis is led by President and Chief Executive Officer John West, who brings more than two decades of leadership in biotechnology and personalized medicine. Under his direction, the Company has grown its scientific and operational teams, investing in automation, data analytics and assay innovation. With a focus on comprehensive genomic insights, Personalis aims to advance the understanding of cancer biology and improve patient outcomes through precision diagnostics.
